अक्तूबर, 1986, फरवरी, 1987 और मार्च, 1987 में एक-एक रैक उपलब्ध कराया गया ।

(ख) जी नहीं ।

(ग) प्रश्न नहीं उठता ।

हावड़ा-झांसी रेल संपर्क

1175. डा० गोविन्द दास रिछारिया : क्या रेल मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या हावड़ा को झांसी से रेलगाड़ी सेवा से जोड़ने का कोई प्रस्ताव सरकार के विचाराधीन है ; और

(ख) यदि हां, तो उसका ब्यौरा क्या है और उक्त प्रस्ताव को कब तक कार्यान्वित किये जाने की सम्भावना है और यदि नहीं, तो उसके क्या कारण हैं ?

रेल मंत्रालय के राज्य मंत्री (श्री माधवराव सिंधिया) : (क) और (ख) कानपुर के रास्ते 43/44 मेल और 7/8 एक्सप्रेस से एक ब्रू यान सेवा पहले ही उपलब्ध है जिसका यात्री झांसी से उपयोग करते है ।

Marketing of Dipyrone in the Country

1176. SHRI RAFIQUE ALAM; Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether it is a fact that Dipyrone is being marketed in the country by Various manufacturers under different names;

(b) if so, the names under wnich this is being marketed;

(c) whether it is a fact that this drug is extremely toxic with wide range of side effects;

(d) whether it ig a fact that this drug has been withdrawn in number of countries including Australia, Bangladesh, Denmark, Italy, Japan. Norway, Saudi Arabia, Singapore, Sweden, UK, USA and Venezuela due to fatal agranulcytosis;

(e) whether it is also a fact that this drug has been put under severe •restriction for the, us? in West Ger many. _,

(f) whether it is a fact that German Company is having maximum sal$_e$ of thig drug in India beside other companies; and

(g) if so, names of formulations based on this drug, it$_s$ sales per year and reasons for allowing it for human consumption?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) Yes, Sir.

(b) Dipyrone is another name of Analgin. The popular names under which the drug is marketed in the country are Analgin (IDPL), Noval-gin (Hoechst).

(c) The drug is not extremely toxic with wide range of side effects.

(d) and (e) While the drug Analgin continues to be marketed in many countries, it has been withdrawn in some countries in the belief that the drug causes agranulocytosis (fall in number of white blood cells) in significant nnmber of population. However, Boston Epidemiological study which has been concluded recently has shown that the incidence of agranulocytosis due to the drug analgin is not significant enough for withdrawal of the drug. While the sale of the drug Analgin has been put under restriction in Germany now against the prescription of a Doctor, the drug was required to be sold aeainst prescription of Registered Medical Practioner right from the introduction of tbis drug in India.

(f) M/s Hoechst (I) Ltd. is having a s'zable turnover of formulations ba sed on Dipyrone (Analgin) in India, besides several other companies.

(g) Sales turnover of formulations Ss not monitored. Names of some major formulations based on this drug are ffive$_n$ below: —

(1) Novalgin
(2) Baraigan f3) OxaVm
(4) Algesin-O
(5) Ultragin
(6) Zimolgin-A

The rensons for allowing the drugs for humsn consumption has been given in the' reply t_0 parts (d) and (e) of the qnestion.

Import of Serum/Vaccines

1177. SHRI RAFIQUE ALAM: Wili th_e Minister of HEALTH AND FAMILY WELFARE be pleased to refer to the answer to Starred Question 219 given in the Rajya Sabha on 7th May, 1986 and state:

(a) the number of consignments of each of serum, human and veterinary vaccines imported during the last three years, year-wise, along with the quantity and country of import;

(b) the number of samples of each serum, human and veterinary vaccines were drawn;

(c) the names of the laboratories where each sample was tested along with its report

ed) if these were not tested, what were the reasons for non-testing of each batch;

(e) whether it is a fact that most of the imported sera and vaccines are of sub-standard quality due to the reasons that either the samples are not tested or facilities to test them in the country are not 'ailable; and

(f) if so, the names if vaccines and sera for which testing facilities are not available and by when the same will be made available?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) to (c) The information is being collected .and will be laid on the table of the iSabha.

(d) and (e) Only vaccines con forming to the prescribed conditions of strength and quality are allowed to be imported. Under the normal circumstances vaccines, for which testing facilities are available, are tested when imported into the country for the flrst time. For subsequent consignments from the same source random sampling i_5 done. Under exceptional circumstances, such as epidemic, vaccines are released without testing. However, it may be added that in al] the cases of human vaccines, the vaccine is released only after a batch release certificate, issued by the health authorities of the exporting countries, is furnished by the importer.

(f) Testing facilities for Measles—Mumps and Rubella (MMR) are not available for the present but are being developed indigenously.

Appointment of Chairman and Mana. ging Directeor of Co_cMn Shipyard Limited, Cochin

1178. SHRT BIR BHADRA PRATAP SINGH: Will the Minister of SURFACE TRANSPORT be pleased to state:

(a) whether it is a fact that the selection for Chief Managing Director and Directors in Cochin Shipyard Limited. Cochin was held without issuing the press advertisement.

(b) whether no candidates from CSL and other shipyard were called for interview;

(c) if so, the details thereof; and

(d) what action is being taken to revise the selection process in order to enable the Public. Enterprises Selection Board to select right candidates for the above posts?

THE MINTSTER OF STATE OF THE MINISTRY OF SURFACE TRANSPORT (SHRI RAJESH PILOT): (al to (d) The selection to the Post of Chairman and Managing Director CSL was madp as per the laid down guidelines for filling un the posts of ton Executives of Public Sector Undertakings. promulgated *vido* Ministrv of Finance's O.M. No 5(24)|77-BPE-PESB dated 5th August 1977, The candidates invited for the